Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 2
2011 2
2012 2
2013 1
2014 1
2015 4
2016 3
2017 3
2018 2
2019 6
2020 5
2021 5
2022 8
2023 9
2024 5
2025 14

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

65 results

Results by year

Filters applied: . Clear all
Page 1
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia.
Brown JR, Seymour JF, Jurczak W, Aw A, Wach M, Illes A, Tedeschi A, Owen C, Skarbnik A, Lysak D, Eom KS, Šimkovič M, Pavlovsky MA, Kater AP, Eichhorst B, Miller K, Munugalavadla V, Yu T, de Borja M, Ghia P; AMPLIFY investigators; AMPLIFY Investigators. Brown JR, et al. N Engl J Med. 2025 Feb 20;392(8):748-762. doi: 10.1056/NEJMoa2409804. Epub 2025 Feb 5. N Engl J Med. 2025. PMID: 39976417 Clinical Trial.
Waldenstrom's Macroglobulinemia: An Update.
Mazzucchelli M, Frustaci AM, Deodato M, Cairoli R, Tedeschi A. Mazzucchelli M, et al. Among authors: frustaci am. Mediterr J Hematol Infect Dis. 2018 Jan 1;10(1):e2018004. doi: 10.4084/MJHID.2018.004. eCollection 2018. Mediterr J Hematol Infect Dis. 2018. PMID: 29326801 Free PMC article. Review.
BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib.
Bonfiglio S, Sutton LA, Ljungström V, Capasso A, Pandzic T, Weström S, Foroughi-Asl H, Skaftason A, Gellerbring A, Lyander A, Gandini F, Gaidano G, Trentin L, Bonello L, Reda G, Bödör C, Stavroyianni N, Tam CS, Marasca R, Forconi F, Panayiotidis P, Ringshausen I, Jaksic O, Frustaci AM, Iyengar S, Coscia M, Mulligan SP, Ysebaert L, Strugov V, Pavlovsky C, Walewska R, Österborg A, Cortese D, Ranghetti P, Baliakas P, Stamatopoulos K, Scarfò L, Rosenquist R, Ghia P. Bonfiglio S, et al. Among authors: frustaci am. Blood Adv. 2023 Jun 27;7(12):2794-2806. doi: 10.1182/bloodadvances.2022008821. Blood Adv. 2023. PMID: 36696464 Free PMC article.
Salvage treatment after covalent BTKi failure: An unmet need in clinical practice in Waldenstrom macroglobulinemia.
Frustaci AM, Zappaterra A, Galitzia A, Visentin A, Merli M, Rizzi R, Ferrarini I, Ferrero S, Innao V, Baratè C, Zinzani P, Puccini B, Autore F, Tani M, Ferrari A, Catania G, Nicolosi M, Pasquale R, Motta M, Murru R, Gambara S, Rezzonico F, Varettoni M, Cencini E, Lista E, Danesin N, Granelli BM, Deodato M, Piazza F, Tedeschi A. Frustaci AM, et al. Hemasphere. 2025 Feb 20;9(2):e70094. doi: 10.1002/hem3.70094. eCollection 2025 Feb. Hemasphere. 2025. PMID: 39981189 Free PMC article. No abstract available.
Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial.
Tedeschi A, Frustaci AM, Condoluci A, Coscia M, Chiarle R, Zinzani PL, Motta M, Gaidano G, Quaresmini G, Scarfò L, Catania G, Deodato M, Jones R, Tabanelli V, Griggio V, Stüssi G, Calleri A, Pini K, Cairoli R, Zenz T, Signori A, Zucca E, Rossi D, Montillo M. Tedeschi A, et al. Among authors: frustaci am. Lancet Oncol. 2024 Oct;25(10):1298-1309. doi: 10.1016/S1470-2045(24)00396-6. Epub 2024 Sep 10. Lancet Oncol. 2024. PMID: 39270702 Clinical Trial.
Richter transformation in diffuse large B-cell lymphoma in patients with chronic lymphocytic leukemia receiving ibrutinib: risk factors and outcomes.
Pepe S, Vitale C, Giannarelli D, Visentin A, Sanna A, Frustaci AM, Olivieri J, Quaglia FM, Gozzetti A, Sportoletti P, Murru R, Innocenti I, Reda G, Pupo L, Levato L, Porrazzo M, Ilariucci F, Moia R, Foglietta M, Rigolin GM, Chiurazzi F, Trastulli F, Cellini A, Deodato M, Martino E, Laurenti L, Coscia M, Cuneo A, Gaidano G, Rossi D, Gentile M, Mauro FR. Pepe S, et al. Among authors: frustaci am. Leukemia. 2025 Aug;39(8):1883-1891. doi: 10.1038/s41375-025-02666-8. Epub 2025 Jun 25. Leukemia. 2025. PMID: 40562789 Free PMC article.
Venetoclax-based regimens in octogenarian patients with CLL: efficacy, safety, and comparison to BTKi in a multicenter cohort.
Serafin A, Cellini A, Martino EA, Mazzetto F, Angotzi F, Frustaci AM, Marchetti M, Moia R, Sanna A, Riemma C, Cibien F, Noto A, Lista E, Foglietta M, Vitale C, Innao V, Bullo M, Lovato E, Ferrarini I, Andriola C, Ballotta L, Innocenti I, Fresa A, Favrin G, Varettoni M, Santambrogio E, Orsucci L, Pasquale R, Moratti M, Laurenti L, Coscia M, Sportoletti P, Marasca R, Mauro FR, Patti C, Derenzini E, Scarfò L, Ghia P, Cuneo A, Tedeschi A, Trentin L, Gentile M, Visentin A. Serafin A, et al. Among authors: frustaci am. Blood Adv. 2025 Jul 22;9(14):3576-3584. doi: 10.1182/bloodadvances.2025015818. Blood Adv. 2025. PMID: 40239056 Free PMC article.
65 results